
==== Front
BMC Psychol
BMC Psychol
BMC Psychology
2050-7283
BioMed Central London

1974
10.1186/s40359-024-01974-5
Study Protocol
A prospective non-randomized controlled trial testing the effectiveness of psychotherapeutic inpatient treatment of Post-COVID-19 syndrome - study protocol
Koller Katharina Katharina.koller@uk-erlangen.de

12
Kastel-Hoffmann Silke 12
Herold Regina 12
Morawa Eva 12
Lieb Marietta 12
Krehbiel Johannes 12
Hohberger Bettina 3
Erim Yesim 12
1 grid.5330.5 0000 0001 2107 3311 Department of Psychosomatic Medicine and Psychotherapy, Universitätsklinikum Erlangen, Friedrich- Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
2 https://ror.org/0030f2a11 grid.411668.c 0000 0000 9935 6525 Post-COVID Center, Universitätsklinikum Erlangen, Erlangen, Germany
3 grid.5330.5 0000 0001 2107 3311 Department of Ophthalmology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen- Nürnberg (FAU), Erlangen, Germany
16 9 2024
16 9 2024
2024
12 48625 7 2024
29 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Introduction

In addition to physical symptoms such as dyspnea, fatigue, post-exertional malaise, and pain, a subgroup of patients with Post-COVID-19 syndrome (Post-Acute Sequelae of COVID-19, PASC) suffers from mental illnesses such as anxiety, depression, and neurocognitive impairments. To date, there are no causal treatments available for PASC. While initial studies show that psychotherapy improves psychological symptoms, PASC-related fatigue, and psychosocial functioning, further research is needed to evaluate the effectiveness of psychotherapeutic treatment for PASC.

Methods and analysis

This study presents a non-randomized controlled trial aimed at evaluating the effectiveness of a five-week multimodal inpatient psychosomatic treatment program for individuals experiencing PASC symptoms and comorbid mental illness. A total of 118 patients presented at the Post-COVID Center at the Universitätsklinikum Erlangen will be assigned to the intervention group receiving inpatient psychosomatic treatment or the control group receiving treatment as usual. The inclusion criteria for the intervention group are a diagnosis of PASC and at least one condition of mental distress and problems with coping with illness. The primary objective of the intervention is to reduce mental ailments, including depression and anxiety, as well as neurocognitive deficits, and to address PASC symptoms such as fatigue and pain. The core elements of the treatment are psychotherapy in individual and group settings, medical treatment, neurocognitive training, and physical therapy, adapted to the individual’s capacity and oriented towards the concept of pacing. After enrollment, participants will undergo a 6-month follow-up to assess long-term results and the sustainability of the intervention effects.

Discussion

This study examines the effectiveness of inpatient psychotherapeutic treatment in PASC patients with comorbid mental illness in comparison with a control group based on treatment as usual. The results of the study can contribute to the development of evidence-based interventions to address the complex needs of patients with PASC and comorbid mental illness.

Trial registration

German Clinical Trial Register (DRKS), retrospectively registered 15.02.2024 DRKSID DRKS00033562.

Supplementary Information

The online version contains supplementary material available at 10.1186/s40359-024-01974-5.

Keywords

COVID-19
Post-COVID syndrome
Fatigue
Mental illness
Psychotherapy
Coping with illness
Universitätsklinikum Erlangen (8546)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

The World Health Organization (WHO) characterizes Post-COVID-19 syndrome (Post-Acute Sequelae of COVID-19, PASC) as a condition where new or ongoing symptoms arise three months after the initial SARS-CoV-2 infection, lasting for a minimum of twelve weeks and lacking an alternative explanation [1, 2]. Among those infected with SARS-CoV-2, 6.2% experience at least one of three PASC symptom clusters, which include persistent fatigue with bodily pain or psychological problems, neurocognitive problems, or ongoing respiratory issues. Prevalence rates of PASC vary between different studies and subgroups, with the highest rates among women and those who required hospitalization for the initial SARS-CoV-2 infection [3–5]. Worldwide, physicians face considerable difficulties in treating PASC due to the absence of specific biological markers for clear diagnostic classification and the lack of causal therapies, complicating effective treatment of PASC and raising economic costs due to frequent contact with general practitioners and specialist physicians [6]. For those affected, PASC not only significantly impairs their quality of life [7], but also their ability to work. In 2022 alone, the German Pension Insurance reported 21,000 inpatient rehabilitation treatments for PASC [8] and 1,000 approved pensions for those unable to return to work due to the condition [9].

Approximately one-fifth of PASC patients also reveal mental health comorbidities such as anxiety, depression, symptoms of PTSD, and disruptions in sleep patterns [10, 11], with a prevalence of depressive and anxiety symptoms 12 months after SARS-CoV-2 infection at 23% and 22%, respectively. The prevalence of insomnia was found to be 12% [12], while other studies estimated sleep disturbances to be as high as 45% [13]. Posttraumatic symptoms after SARS-CoV-2 infection range from 6.5 to 42.8%, particularly high in those who had severe SARS-CoV-2 infection [14]. There is also accumulating evidence that preexisting psychological and psychosomatic conditions, such as symptoms of depression and anxiety, loneliness, and perceived stress, are vulnerability factors for the appearance of PASC symptoms [15]. Notably, depressive symptoms along with anxiety symptoms were found to persist for an extended period [16–18] and can significantly impact an individual’s quality of life [7].

One possible explanation for the occurrence of accompanying mental illness in PASC patients may be the difficulties in coping with illness, a concept explained by the stress-coping model [19]. The onset of a chronic illness is typically associated with psychosocial stress arising from e.g. physical limitations, the unpredictability of the disease’s progression, threats to social roles and activities, financial problems, and disruptions in self-concept and emotional well-being [20]. Effective stress management depends on evaluating stressors and having adequate coping resources, e.g. psychological stability or social support [19]. When stress exceeds these resources, the likelihood of mental illness increases [21, 22].

At the same time, psychosocial factors, in addition to biomedical factors, play an important role in maintaining and exacerbating persistent physical symptoms, defined as distressing somatic complaints lasting several months or longer. Psychosocial factors can include cognitive-perceptual and emotional mechanisms such as symptom focusing, catastrophizing interpretations, and disease-related fears or behavioral processes such as avoidance behavior, physical inactivity, and deconditioning [23]. This interplay of biomedical and psychosocial factors is also discussed for the persistence of physical symptoms in PASC [24, 25]. An initial study showed that psychological distress associated with persistent symptoms that occurred during the first year of the pandemic predicted the presence of at least one persistent symptom 6–10 months later [26]. This finding underscores the possible role of psychosocial stress in the disease course of PASC.

Initial studies have shown positive effects of psychotherapeutic interventions in PASC in outpatient and rehabilitative settings. Cognitive behavioral interventions applied in an outpatient setting lead to an improvement in fatigue symptoms and improved coping in PASC patients [27, 28]. Multimodal inpatient rehabilitation treatment with psychotherapeutic elements showed a reduction in psychological and somatic symptoms and an improvement in activity and social participation [29]. However, while psychotherapeutic interventions for PASC have been evaluated in outpatient and rehabilitation settings, results on the effectiveness of psychotherapeutic interventions established in acute care of psychosomatic treatment are lacking. When we refer to “psychosomatic treatment” in the following, we mean inpatient multimodal, focus-orientated psychotherapy for the treatment of PASC patients with mental disorders.

To address mental disorders and coping with PASC symptoms, we will use psychotherapeutic interventions which include e.g., psycho-education, coping with fear of progression, working on resources, relaxation techniques, working on emotions, and cognitive methods such as cognitive restructuring [30]. These approaches are already used as interventions for chronic illnesses, e.g. in psycho-oncological care and rehabilitation of chronic diseases, and can help patients manage their illness more effectively [31, 32]. To treat more physical symptoms of PASC, such as breathing problems and fatigue, we will supplement psychotherapeutic interventions with physiotherapy. Research on other chronic diseases, such as multiple sclerosis, has demonstrated the beneficial effects of aerobic exercises on fatigue symptoms [33, 34]. Furthermore, aerobic exercise was shown to be effective and safe as an early intervention after (severe) SARS-CoV-2 infection [35] as well as a treatment to improve PASC-related fatigue and functional capacity [29, 36, 37]. When combined with the concept of pacing - a self-management strategy that involves tailoring physical and cognitive activity to the individual’s energy levels [2]- aerobic exercise can be safely incorporated without risking post-exertional malaise (PEM), a worsening of chronic fatigue symptoms after minimal physical or mental exertion [38]. Various studies have shown that activity pacing positively impacts fatigue severity in chronic diseases [39–41]. Aerobic exercise can also improve neurocognitive functioning, which has been shown in a rehabilitation exercise program that incorporates resistance, endurance, and balance training, as well as education and pacing strategies [36]. To further alleviate the neurocognitive impairments, we will use computerized neurocognitive training, which has shown promising results in PASC patients according to initial studies. [42].

In order to appropriately tackle all these issues of PASC, an integrated multimodal approach in a psychosomatic treatment setting is ideal. In our trial, we are testing this inpatient psychosomatic PASC setting for effectiveness with a control group. Key endpoints include changes in the severity of PASC (primary outcome), as well as overall physical and mental health symptoms such as insomnia, fatigue, PEM, neurocognitive impairments, anxiety, and depression (secondary outcomes). Additional secondary outcome measures include perceived social support, distress, sense of coherence, quality of life, and coping with illness. Moreover, outcomes like healthcare utilization and treatment satisfaction are assessed.

Objectives and hypothesis

The objective of the proposed trial is to address PASC symptoms and provide an effective treatment for PASC patients with accompanying mental illness. We aim to assess the effectiveness of a five-week inpatient treatment in the Department of Psychosomatic Medicine and Psychotherapy at Universitätsklinikum Erlangen.

Primary hypothesis

We expect the intervention to be superior to treatment as usual (TAU) regarding a significantly lower mean of PASC symptoms measured by the Post-COVID Syndrome Scale (PCS Score) post-treatment and at 6 months follow-up.

Secondary hypothesis

We expect the intervention to be superior to TAU in terms of reducing depression and anxiety symptoms, fatigue, sleeping problems, and perceived stress that relates to the illness as well as improving neurocognitive functions, patient competence to cope with illness, perceived social support, overall quality of life, and sense of coherence.

Methods

For reporting the outcomes of inpatient psychosomatic treatment for PASC, the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) reporting guideline will be used [43]. In case of important protocol modification, it will be reported to the sponsor and the ethics committee, and the trial registration will be updated. Results will be published in peer-reviewed journals, conference presentations, and among self-help organizations.

Study design

This is a prospective non-randomized controlled trial. It is a two (group: intervention and control) by three (time: pre-treatment, 5 weeks, 6 months) repeated measures factorial design. The overall study design is illustrated in Fig. 1 and Table 1. In T0 sociodemographic data, medication, and use of previous psychotherapeutic inpatient or outpatient treatments, as well as data on health behavior (e.g. smoking, alcohol consumption, etc.) of the patients will be collected. Participants in the intervention group will complete a comprehensive web-based questionnaire battery at three time points: at the time of admission to the hospital setting (T0), at the end of inpatient treatment five weeks later (T1), and 6 months after discharge from the hospital setting (T2). The control group will accomplish the questionnaire within a time frame of around 6 months after presentation at the Post-COVID Center of the Universitätsklinikum Erlangen (T0), five weeks after T0 (T1), and 6 months after T0 (T2). The questionnaires at T0, T1, and T2 will be made available web-based via a link and a password. Participants who drop out of the intervention or control group will be reported in the final results. Before participation, written informed consent must be given. A schematic overview of the trial flow is given in Fig. 1. The instruments used at each time point are displayed in Table 1.

Table 1 Overview of the assessment schedule for both groups

Measures	Assessment time points	
Baseline
(T0)	5 weeks later (T1)	6-month follow-up (T2)	
Sociodemographic variables	X			
Health behavior	X	X	X	
Use of PASC-specific treatments		X**	X	
Use of PASC-specific outpatient or inpatient psychotherapeutic treatment	X	X**	X	
Primary outcome	
PASC (PCS Score)	X	X	X	
Secondary outcomes	
Somatic, Depression, and Anxiety symptoms (PHQ-15;

PHQ-9; GAD–7)

	X	X	X	
Sleep (ISI)	X	X	X	
Fatigue (FSS)	X	X	X	
Post-exertional malaise (PEM)	X	X	X	
Social support (ESSI)	X	X	X	
Sense of coherence (SOC-3)	X	X	X	
Distress (PSS-4)	X	X	X	
Somatic symptom disorder (SSD-12)	X	X	X	
Patients’ competence to cope with illness (PUK-2)	X	X	X	
Quality of life (SF-36)	X	X	X	
Satisfaction with treatment			X*	
Neurocognitive testing*	
Declarative verbal memory (retrieval and recognition of VLMT)	X	X		
Cognitive processing speed and cognitive flexibility (TMT)	X	X		
Numerical short-term memory and working memory (Digit span backwards of WMS – R)	X	X		
Attention and concentration (d2 – R)	X	X		
Formal lexical and semantic verbal fluency (RWT)	X	X		
* Only for the intervention group

** Only for the control group

PCS Score, Post-COVID Score; PHQ-15, Patient Health Questionnaire-15; PHQ-9, Patient Health Questionnaire-9; GAD – 7, Generalized Anxiety Disorder Scale – 7; ISI, Insomnia Severity Index; FSS, Fatigue Severity Scale; PEM, Post-Exertional Malaise; ESSI, ENRICHD Social Support Instrument; SOC-3, Sense of Coherence Scale-3; PSS-4, Perceived Stress Scale-4; SSD-12, Somatic Symptom Disorder-12; PUK-2, Patient Competence in Coping with Cancer Questionnaire adapted for PASC symptoms; SF-36, Short Form Health Survey Questionnaire; VLMT, Verbal Learning and Memory Test; TMT, Trail Making Test; WMS-R, Wechsler Memory Scale-R; d2-R, Attention and Concentration Test; RWT, Regensburger Verbal Fluency Test

Fig. 1 Trial flow

Participant’s eligibility and recruitment

Patients will be recruited from the Post-COVID Center at the Universitätsklinikum Erlangen. All study patients will receive comprehensive interdisciplinary diagnostics at the Post-COVID Center. After detailed information and consent, eligible patients will be allocated to either a control or intervention group.

Inclusion criteria

Aged 18 years or older.

Confirmed (e.g. positive PCR or antigen test) SARS-CoV-2 infection and subsequent PASC: complaints that are still present more than 12 weeks after the onset of SARS-CoV-2 infection and cannot be explained otherwise.

Written informed consent to participate in the study.

Sufficient knowledge of the German language to participate in the study.

Treatment group: indication for inpatient psychosomatic treatment due to:

Diagnosis of mental disorder (ICD-10; International Classification of Diseases, 10th Revision).

Limitations that significantly reduce the ability to manage everyday life (e.g. the ability to maintain daily structure).

and/ or

Subjective stress so great that the quality of life and everyday resilience are significantly limited.

6) Control group: depressive symptoms in self-assessment (PHQ-9 ≥ 10).

Exclusion criteria

Severely physically impaired patients (predominantly bedridden).

Unique or main diagnosis of substance abuse (F10 – F19), schizophrenia, psychosis (F20 – F229) or organic psychiatric disorders (F00 – F09).

Suicidality.

Control group: utilization of PASC-specific outpatient or inpatient psychotherapeutic treatment or psychosomatic rehabilitation during 5 weeks of treatment.

Control group

The control group will consist of PASC patients for whom there is an indication for inpatient psychosomatic treatment (depressive symptoms in self-assessment: PHQ-9 ≥ 10), but who do not take up the treatment. After group allocation, participants in the TAU condition will have no access to the inpatient psychosomatic treatment, but will not be restrained from using any form of care for PASC-related symptoms. Treatment as usual for PASC patients can entail follow-up contacts with their treating physician or general practitioner, physical training, occupational therapy, or rehabilitation. At T0, T1, and T2, participants of the control group will be questioned about the received psychotherapeutic inpatient or outpatient treatment.

Intervention

The intervention consists of a five-week inpatient psychosomatic treatment according to an integrative comprehensive concept of depth psychological and cognitive-behavioral therapy. The patients will be admitted in closed groups of 5 to 6 patients each.

All therapists will be physicians in advanced or completed specialized training in psychosomatic medicine and psychologists in advanced or completed training in clinical psychotherapy, physiotherapists, registered nurses, social workers, and psychotherapists for integrative body and movement therapy. At the beginning of the study, all therapists will receive several training courses on psychosomatic aspects of PASC, the PASC guideline, the PASC concept for inpatient psychotherapy, immunological principles of PASC and fatigue, and the treatment of PASC in physiotherapy and aerobic exercise therapy.

We have adopted parts of the concept from the working group of Köllner et al. [44] and adapted it to our psychosomatic inpatient setting. The psychotherapeutic focus of the treatment is on coping with the PASC symptoms and treating comorbid mental symptoms that have arisen as a result of the chronic illness. Table 2 provides an overview of the treatment interventions, addressing the key aims of each element. Four cornerstones of treatment are applied in addition to our regular multimodal, focus-orientated psychotherapy concept. Figure 2 illustrates these cornerstones, which are explained in detail below.

Fig. 2 Four cornerstones of PASC specific inpatient psychosomatic treatment

Medical treatment Our comprehensive multidisciplinary medical assessment will include detailed medical examination at the beginning and end of treatment, with evaluations by specialists if new symptoms arise and weekly medical consultations.

Neurocognitive training Neurocognitive training will be carried out independently with the digital health application NeuroNation MED [45] at least twice a week. The individually customized training plan and the adaptive difficulty level will be tailored to the user’s needs. NeuroNation MED contains over 35 multimodal exercises that target the domains of memory, attention, processing speed, and reasoning. The neurocognitive training will be continued after discharge from inpatient treatment. This is made possible because NeuroNation MED is carried out on a smartphone.

Psychotherapy Our therapeutic approach is characterized by a permanent validation of the psychological symptoms resulting from a somatic illness, in this case, SARS-CoV-2 infection, acceptance of the status quo and at the same time strengthening self-efficacy and resource orientation. The focus of our psychotherapy concept is on developing an understanding of PASC from a biopsychosocial perspective and learning functional coping skills, taking into account the physical, psychological, and social challenges of PASC. The treatment is based on established, effective methods of cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT). To avoid post-exertional malaise (PEM) the focus of psychoeducation is on learning the 3P principle [46], including pacing, planning, and prioritizing. Pacing means, for example, dividing tasks and activities into smaller sections throughout the day and taking breaks. Planning refers to the scheduling of support and the prior provision of aids for activities while prioritizing means setting realistic goals and assessing the importance and necessity of various tasks [2]. To ensure pacing, therapies are individually tailored, meaning patients will be allowed to skip therapies at any time as required or cancel them early. This serves as a training ground for recognizing and setting one’s boundaries.

Physical therapy will take place in close cooperation and coordination with the Department of Physical and Rehabilitative Medicine at the Universitätsklinikum Erlangen. There will be weekly interdisciplinary meetings to discuss the patient’s current status. The so-called CoFit Training Group (e.g. circuit training, stretching exercises, balance training, breathing therapy, back exercises, etc.) will take place in a group setting twice a week for 30 min each. When indicated, patients will also receive additional pulse-controlled ergometer training in a group setting, depending on their fitness level. Our physiotherapeutic treatment concept for post-COVID will take up established physiotherapeutic treatment approaches for fatigue (e.g. for multiple sclerosis) [33, 34] and will include pacing as a central technique in all therapies. Additionally, patients will rate their symptoms and their exertion rate on the Borg breathlessness scale [47]. This ensures that individual resilience will be taken into account in the CoFit training group and ergometer training and that physiotherapy will continuously be adapted to individual’s progress.

Table 2 Overview of the frequency and duration, and key aims of psychosomatic treatment for PASC

	Frequency and duration	Key aims	
Psychotherapeutic interventions	
PASC psychoeducation group	2x/ week for 90 min	Psychoeducation and development of an individualized disorder model; dealing with PASC, changes in lifestyle and self-esteem; communicating about PASC, coping skills, and psychological mechanisms	
Individual psychotherapy	2x/ week for 50 min and 25 min	
Family meeting	1 × 60 min when indicated	Involving the social environment to strengthen social support and give information on PASC	
Mindfulness walking group	2x/ week for 30 min	Promoting the recognition of physical limits following the concept of pacing, self-expression, and introspection and reducing distress	
Relaxation training group (progressive muscular relaxation and yoga)	2x/ week for 30 min	
Mindfulness training group	2x/ week for 30 min	
Integrative body and movement therapy group	1x/ week for 90 min	Improving patients’ self-awareness and body awareness, helping patients accept their current state, promoting self-efficacy and self-care	
Neurocognitive training	
Neurocognitive training	2x/ week for 30 min	Improving patients’ neurocognitive impairments by individually tailored exercises on the digital health application NeuroNation MED	
Medical treatment	
Medical consultation hour	1x/ week for 20 min and when indicated	Addressing medical problems, answering medical questions, if necessary improve adherence to intervention protocols	
Physiotherapy	
CoFit-Training Group	2x/ week for 30 min	Individualized aerobic exercise training to improve physical and mental resilience, reduce oxidative stress, and exhibit positive effects on immune responses	
Individual physiotherapy	When indicated	
Ergometer training group	When indicated	
Additional elements	
Social worker	1 × 60 min	Socio-therapeutic counseling on social security issues and work-related problems	
PASC group visitation	1x/ week for 30 min	Giving and receiving feedback on the course of treatment, coordination, and adjustment of the treatment plan, if necessary improve adherence to intervention protocols	

Outcomes

Primary outcome

The primary outcome are symptoms of PASC at the end of the treatment (T1, see Table 1). To measure those, we will use the PCS-Score. The PCS-Score consists of 12 yes/no questions and covers the entire spectrum of possible PASC symptoms. Each question is given its weighting factor, which assigns a meaning to the corresponding symptom complex. The resulting sum score ranges from 0 (= complete absence of any symptoms) to 59 (= presence of symptoms in each of the 12 symptom complexes). A clinically relevant PASC can be assumed from a PCS Score of 26.25 (high PCS Score). Values between 10.75 and 26.25 indicate an intermediate or moderate PASC. The PCS Score was validated on a German population [48].

Main secondary outcomes

Somatic, depressive, and anxiety symptoms will be evaluated using the German version of the Patient Health Questionnaire Somatic Symptom Scale 15 (PHQ-15), the Patient Health Questionnaire Depression Scale 9 (PHQ-9), and the Generalized Anxiety Disorder Scale-7 (GAD-7) [49–51]. To assess fatigue, we will use the Fatigue Severity Scale (FSS) [52]. Post-exertional malaise will be measured by an adapted German version of the DePaul Post-Exertional Malaise Questionnaire (PEM). The five DSQ PEM items assess the frequency and severity of PEM over a six-month timeframe. Five additional PEM items examine the duration of symptom exacerbation after activity (3 items), whether patients perceived physical and cognitive exhaustion, and whether participants were not exercising because it made their symptoms worse [53, 54]. Sleep disturbances will be quantified using the Insomnia Severity Index (ISI), a validated measure of insomnia severity and its impact on daily functioning [55, 56]. Social support, a key factor in coping with illness and adversity, will be assessed using a validated German version of the ENRICHD Social Support Instrument (ESSI), which captures perceived social support [57]. The short version of the Sense of Coherence Scale (SOC-3) will be used to assess the participants’ perceived ability to cope with stressors and maintain a sense of coherence and meaning in their lives [58]. Perceived stress levels will be measured using the Perceived Stress Scale (PSS-4), a short version of the 14-item Perceived Stress Scale, a widely used instrument for assessing the degree to which situations in one’s life are appraised as stressful [59]. Furthermore, psychological stress specific to somatic symptoms disorder (SSD-12) will be evaluated to capture the stress experienced in response to physical symptoms [60]. Participants’ coping strategies in response to PASC symptoms will be evaluated using the Patient Competence in Coping with Cancer Questionnaire (PUK-2) adapted for PASC symptoms. This measure aims to assess the perceived competence of participants to manage and cope with the challenges posed by ongoing symptoms [61]. Finally, patients’ health-related quality of life will be measured by using the SF-36 [62].

The neuropsychological test battery will consist of the following validated assessments: the Verbal Learning Memory Test (VLMT) [63], the Digit Span Backwards from the Wechsler Memory Scale-Revised (WMS-R) [64], the Trail Making Test (TMT) Parts A and B [65], the d2 Test of Attention [66], and the Regensburger Verbal Fluency Test (RWT) [67]. The VLMT evaluates verbal memory, including delayed free recall (the retention of learned words over time) and recognition ability. The Digit Span Backwards subtest from the WMS-R measures working memory. The TMT assesses visuomotor processing speed, attention, and executive functions such as mental flexibility. The d2 Test of Attention measures selective attention and processing speed. The RWT evaluates both formal lexical (phonemic) fluency and semantic fluency, which are indicators of divergent thinking.

Participant timeline

The schedule of the study including enrollment, intervention, and data assessment is given in Fig. 1 and Table 1.

Data collection, data management, and data storage

Study data will be collected using Heartbeat Medical [68] and REDCap (Research Electronic Data Capture) [69, 70]. Data collection will take place within the clinic and will comply with the legal data protection conditions of the EU GDPR (European Union General Data Protection Regulation). The links for the questionnaires will be personalized, with a password sent by post to activate the link. To obtain the most complete data possible, patients are reminded twice to complete the questionnaires. Data will only be stored and processed in encrypted form. Each participant will be given a research number, so it will not be possible for outsiders to link the data to the individual. Only those responsible for the study, who are bound by medical confidentiality, will have access to a list of personal data and corresponding research numbers. This list will be kept under lock and key. The data will be published anonymously.

Sample size calculation and statistical methods

Sample size calculation was performed with G*Power Version 3.1.9.7 [71, 72]. The sample size calculation is based on testing the primary hypothesis that inpatient psychosomatic treatment leads to a significantly lower mean PCS Score across the first two follow-up assessments (T1 and T2) as compared to treatment as usual. Because of the novelty of PASC, data on our primary outcome, the PCS Score, were not available in this population over different time points. Therefore, we assumed a conservative correlation of 0.5 among repeated measurements and a medium effect size. Based on a medium effect size (f = 0.25) and a power of 85%, a sample size of 98 participants is required, with 49 participants per group. Assuming a conservative dropout of 20%, we will randomize 118 participants, 58 for each condition.

We will perform standard techniques of data preparation with tests of normality and homogeneity and with imputation of missing data in the case of dropouts. Furthermore, we will conduct different descriptive analyses of sociodemographic and medical data. The primary statistical analyses will be a two-way mixed-design Analysis of Variance (ANOVA) with the independent variables being condition (treatment vs. treatment as usual) and time (T0, T1) and condition by time interaction as fixed effects as well as repeated measures ANOVA for the follow-up measurement with repeated measurements. Additionally, we will perform regression analyses to identify potential predictors of treatment outcomes. In all analyses, two-sided p values of < 0.05 are considered to indicate statistical significance. All analyses will be conducted using the statistical software SPSS.

Ethical aspects

We do not believe the trial raises any ethical concerns. We are not aware of any specific risks or disadvantages that may affect patients during the trial, and we do not expect any specific adverse or serious adverse events. Any unexpected adverse or serious adverse events will be documented. During the trial, patients will have access to medical advice or face-to-face contact with a member of the study team (psychologist or physician) at any time, if needed. Side effects of evidence-based psychotherapies are fortunately quite rare. However, potential adverse effects may include lack of treatment response, the emergence of new symptoms, worsening of existing symptoms, strains in the therapist-patient relationship, challenges or changes in work, family, or other social relationships, stigmatization, and the development of a pathological dependence on the therapist [73–75]. In the event of adverse effects, the psychotherapist, physician, or therapist, possibly in consultation with supervisors, will assess the need for further treatment. To prevent adverse events, several measures are implemented, including (i) a training program to raise awareness of adverse events, (ii) special training for physicians, psychologists, and other therapists for the treatment of PASC, and (iii) supervision of psychotherapists, physicians, and other therapists.

The Ethics Committee of the Medical Faculty of Friedrich-Alexander Universität Erlangen-Nürnberg (FAU) has approved the study (22–443_1-B). Written informed consent is required for all patients to participate and will be obtained after proof of verbal and written information and before group allocation. All participating patients can withdraw at any time without disadvantage. In the event of non-consent to participation in the study or withdrawal, patients will not suffer any disadvantages in terms of diagnostics, psychosomatic, or further treatment. Patients will be informed of this in detail in advance.

Discussion

This non-randomized controlled study addresses the critical need for effective treatment strategies for PASC with comorbid mental illnesses. To the best of our knowledge, this is the first controlled study to examine the effectiveness of inpatient psychotherapy in PASC patients with comorbid mental illness. Existing evidence suggests that psychotherapeutic interventions can alleviate both mental health symptoms and physical complaints associated with persistent somatic symptoms [76, 77] and chronic illness [78–80], but their adaption to PASC requires further validation.

In Germany, inpatient psychotherapy is a prevalent approach for treating persistent somatic symptoms, particularly in patients with somatic symptom disorder and mental illnesses stemming from difficulties in coping with chronic illness (e.g., cancer, post-transplantation). Both conditions are relevant in PASC, making inpatient psychotherapy a suitable intervention. Treatment protocols for somatic symptom disorder often incorporate interventions of cognitive behavioral therapy (CBT) [81] and psychodynamic short-term therapies [82, 83], both of which are validated in numerous randomized control trials. These interventions can largely be adopted for the treatment of PASC. However, there is one important aspect in which the treatment of PASC differs from the treatment of somatoform disorders. While in inpatient psychotherapy for the treatment of somatoform disorders medical treatments and physical diagnostics are minimized to focus on the psychological context, the focus on the body is an important therapeutic element in PASC, which is primarily used in the concept of pacing. To prevent post-exertional malaise, patients should learn to listen to their body’s signals and better recognize their limits so as not to exceed their resources. Therefore, the treatment of PASC should integrate both physical and psychological factors, acknowledging their combined role in symptom development and maintenance and offering a holistic approach to patient recovery.

If the intervention is shown to be effective in reducing PASC symptoms and improving mental illness, we expect that direct and indirect costs related to PASC will be reduced, particularly in comorbid mental illnesses, which often require extensive and prolonged medical care [84, 85]. Moreover, effective psychotherapeutic treatment could potentially reduce the burden on healthcare systems by improving patients’ ability to manage their symptoms on their own and reducing the excessive use of healthcare services. In addition to that, our treatment can enhance patients’ overall quality of life, daily functioning, and social participation by alleviating symptoms of anxiety, depression, fatigue, and neurocognitive impairments.

In case the intervention is shown to be effective, implementation of the treatment of PASC in inpatient psychotherapy could have a large public health relevance. Furthermore, the findings of this study could have significant implications for the outpatient psychotherapeutic treatment of PASC. The success of the intervention could lead to the development of tailored outpatient programs, which would be more accessible to a larger number of patients. This transition could enhance the continuity of care and provide ongoing support for PASC patients, fostering long-term recovery and symptom management.

Strengths and limitations

The study’s strengths lie in its robust control design and comprehensive assessment tools. The use of a control group allows for a comparison of outcomes between patients receiving the intervention and those receiving treatment as usual, providing a clearer understanding of the intervention’s effectiveness. Furthermore, the extensive neurocognitive test battery and the detailed measurement of patient-reported outcomes ensure that a wide range of symptoms and impacts are captured. This comprehensive approach allows for a thorough evaluation of the intervention’s effects on both the physical and mental health aspects of PASC. The prior comprehensive interdisciplinary diagnostics in our Post-COVID Center ensure that participants are adequately diagnosed with PASC and have a significant level of psychological distress, making them suitable candidates for psychosomatic treatment.

Despite these promising aspects of this study, several limitations must be considered. One significant limitation is the non-randomized allocation of patients to the control group, which is based on patients’ choice. This self-selection could introduce bias, as those who choose to participate in the intervention may have different levels of motivation or severity of symptoms compared to those who do not. This could potentially affect the generalizability of the study’s findings. Additionally, the study’s reliance on self-reported measures might introduce response bias. Ensuring a large and diverse sample size, along with rigorous statistical analysis, will be crucial in mitigating these limitations.

In conclusion, this study protocol addresses a critical gap in the treatment of PASC syndrome with comorbid mental illnesses. The potential benefits for both health economic factors and patient quality of life are substantial. While limitations such as the non-randomized control group allocation must be acknowledged, the study’s strengths, including its robust design and comprehensive outcome measurements, provide a solid foundation for evaluating the effectiveness of inpatient psychosomatic treatment for PASC. The findings could have significant implications for the broader application of psychotherapeutic interventions in both inpatient and outpatient settings, ultimately contributing to improved care and outcomes for PASC patients.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Acknowledgements

We would like to thank Prof. Dr Volker Köllner from the Department of Psychosomatic Medicine at the Rehabilitation Center Seehof for giving us insights into his PASC-specific rehabilitation concept and for encouraging us to establish a PASC-specific inpatient psychosomatic treatment at the Department of Psychosomatic Medicine and Psychotherapy at Universitätsklinikum Erlangen. 

Author contributions

YE conceived the initial idea for the project. Funding of this trial was obtained by BH and YE. YE supervises the study. YE is the principal investigator. KK, SKH RH, ML, BH, EM, JK, and YE contributed to study design. JK contributed to the recruitment of patients. EM and KK contributed to the statistics. SKH, JK and YE contributed to the development of the intervention and to the training and supervision of therapists. KK, RH, ML and EM are responsible for participant inclusion and data collection. KK drafted this article. All authors read and approved the final manuscript. Katharina Koller: The present work was performed in partial fulfillment of the requirements for obtaining the degree “Dr. rer. biol. hum.” at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU).

Funding

Open Access funding enabled and organized by Projekt DEAL. This study is funded by the Bavarian Health and Food Safety Authority (LGL): disCOVer 2.0 (Gesamt-2490-PCS-2023-V6). The LGL was not involved in the design of the study. They will further not be involved in data collection, data management, statistical analyses and publishing study results.

Open Access funding enabled and organized by Projekt DEAL.

Data availability

No datasets were generated or analysed during the current study.

Declarations

Human ethics and consent to participate

The Ethics Committee of the Medical Faculty of Friedrich-Alexander Universität Erlangen-Nürnberg (FAU) has approved the study (22–443_1-B). Written informed consent is required for all patients to participate and will be obtained after proof of verbal and written information and before group allocation.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Abbreviations

FAU Friedrich Alexander Universität Erlangen-Nürnberg

PASC Post Acute Sequelae of COVID-19

WHO World Health Organization

PTSD Post-traumatic stress disorder

PEM Post-exertional malaise

TAU Treatment as usual

PCS Score Post-COVID Score

PHQ-15 Patient Health Questionnaire-15

PHQ-9 Patient Health Questionnaire-9

GAD-7 Generalized Anxiety Disorder Scale – 7

ISI Insomnia Severity Index

FSS Fatigue Severity Scale

ESSI Experienced Social Support Index

SOC-3 Sense of Coherence Scale-3

PSS-4 Perceived Stress Scale-4

SSD-12 Somatic Symptom Disorder Scale-12

PUK-2 Patient Competence in Coping with Cancer Questionnaire adapted for PASC symptoms

SF-36 Short Form Health Survey Questionnaire

WMS-R Wechsler Memory Scale-R

VLMT Verbal Learning and Memory Test

TMT Trail Making Test

d2-R Attention and Concentration Test

RWT Regensburger Wortflüssigkeits-Test

PCR Polymerase Chain Reaction

SPIRIT Standard Protocol Items: Recommendation for Interventional Trials

ICD-10 International Classification of Diseases, 10th Revision

CBT Cognitive-Behavioral therapy

ACT Acceptance and Commitment therapy

REDCap Research Electronic Data Capture

EU GDPR European Union General Data Protection Regulation

ANOVA Analysis of Variance

SPSS Statistical Package for the Social Sciences

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. World Health Organization. Post Covid-19 condition (Long COVID). 2022 https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition Accessed 20 Mar 2024.
2. Koczulla AR Ankermann T Behrends U Berlit P Böing S Brinkmann F S1 guideline Post-COVID/Long-COVID Pneumologie 2021 75 11 869 900 10.1055/a-1551-9734 34474488
Koczulla AR, Ankermann T, Behrends U, Berlit P, Böing S, Brinkmann F, et al. S1 guideline Post-COVID/Long-COVID. Pneumologie. 2021;75(11):869–900.34474488 10.1055/a-1551-9734
3. Abdel-Gawad M Zaghloul MS Abd-Elsalam S Hashem M Lashen SA Mahros AM Post-COVID-19 syndrome clinical manifestations: a systematic review Antiinflamm Antiallergy Agents Med Chem 2022 21 2 115 20 10.2174/1871523021666220328115818 35346011
Abdel-Gawad M, Zaghloul MS, Abd-Elsalam S, Hashem M, Lashen SA, Mahros AM, et al. Post-COVID-19 syndrome clinical manifestations: a systematic review. Antiinflamm Antiallergy Agents Med Chem. 2022;21(2):115–20.35346011 10.2174/1871523021666220328115818
4. Collaborators GBoDLC Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021 JAMA 2022 328 16 1604 15 10.1001/jama.2022.18931 36215063
Collaborators GBoDLC. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604–15.36215063 10.1001/jama.2022.18931
5. Morawa E Krehbiel J Borho A Herold R Lieb M Schug C Cognitive impairments and mental health of patients with post-COVID-19: a cross-sectional study J Psychosom Res 2023 173 111441 10.1016/j.jpsychores.2023.111441 37544160
Morawa E, Krehbiel J, Borho A, Herold R, Lieb M, Schug C, et al. Cognitive impairments and mental health of patients with post-COVID-19: a cross-sectional study. J Psychosom Res. 2023;173:111441.37544160 10.1016/j.jpsychores.2023.111441
6. Gandjour A Long COVID Costs for the German economy and health care and pension system BMC Health Serv Res 2023 23 1 1 7 10.1186/s12913-023-09601-6 36593483
Gandjour A. Long COVID. Costs for the German economy and health care and pension system. BMC Health Serv Res. 2023;23(1):1–7.36593483 10.1186/s12913-023-09601-6
7. Malik P Patel K Pinto C Jaiswal R Tirupathi R Pillai S Post-acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis J Med Virol 2022 94 1 253 62 10.1002/jmv.27309 34463956
Malik P, Patel K, Pinto C, Jaiswal R, Tirupathi R, Pillai S, et al. Post-acute COVID‐19 syndrome (PCS) and health‐related quality of life (HRQoL)—A systematic review and meta‐analysis. J Med Virol. 2022;94(1):253–62.34463956 10.1002/jmv.27309
8. Deutsche Rentenversicherung. Zahl der Post-COVID-Reha-Anträge gestiegen. 2023 https://www.deutsche-rentenversicherung.de/DRV/DE/Ueber-uns-und-Presse/Presse/Meldungen/2023/230801-zahlen-post-covid-reha.html Accessed 13 May 2024.
9. Ärzteblatt. 1.000 Erwerbsminderungsrenten wegen Long COVID bewilligt. 2023 https://www.aerzteblatt.de/nachrichten/144577/1-000-Erwerbsminderungsrenten-wegen-Long-COVID-bewilligt Accessed 13 May 2024.
10. Zeng N Zhao Y-M Yan W Li C Lu Q-D Liu L A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action Mol Psychiatry 2023 28 1 423 33 10.1038/s41380-022-01614-7 35668159
Zeng N, Zhao Y-M, Yan W, Li C, Lu Q-D, Liu L, et al. A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action. Mol Psychiatry. 2023;28(1):423–33.35668159 10.1038/s41380-022-01614-7
11. Marchi M Grenzi P Serafini V Capoccia F Rossi F Marrino P Psychiatric symptoms in Long-COVID patients: a systematic review Front Psychiatry 2023 14 1138389 10.3389/fpsyt.2023.1138389 37415689
Marchi M, Grenzi P, Serafini V, Capoccia F, Rossi F, Marrino P, et al. Psychiatric symptoms in Long-COVID patients: a systematic review. Front Psychiatry. 2023;14:1138389.37415689 10.3389/fpsyt.2023.1138389
12. Han Q, Zheng B, Daines L, Sheikh A. Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on Post-COVID symptoms. Pathogens. 2022;11(2).
13. Seighali N Abdollahi A Shafiee A Amini MJ Teymouri Athar MM Safari O The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis BMC Psychiatry 2024 24 1 105 10.1186/s12888-023-05481-6 38321404
Seighali N, Abdollahi A, Shafiee A, Amini MJ, Teymouri Athar MM, Safari O, et al. The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis. BMC Psychiatry. 2024;24(1):105.38321404 10.1186/s12888-023-05481-6
14. Schou TM Joca S Wegener G Bay-Richter C Psychiatric and neuropsychiatric sequelae of COVID-19–A systematic review Brain Behav Immun 2021 97 328 48 10.1016/j.bbi.2021.07.018 34339806
Schou TM, Joca S, Wegener G, Bay-Richter C. Psychiatric and neuropsychiatric sequelae of COVID-19–A systematic review. Brain Behav Immun. 2021;97:328–48.34339806 10.1016/j.bbi.2021.07.018
15. Wang S Quan L Chavarro JE Slopen N Kubzansky LD Koenen KC Associations of Depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of Post-COVID-19 conditions JAMA Psychiatry 2022 79 11 1081 91 10.1001/jamapsychiatry.2022.2640 36069885
Wang S, Quan L, Chavarro JE, Slopen N, Kubzansky LD, Koenen KC, et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of Post-COVID-19 conditions. JAMA Psychiatry. 2022;79(11):1081–91.36069885 10.1001/jamapsychiatry.2022.2640
16. van der Feltz-Cornelis C, Turk F, Sweetman J, Khunti K, Gabbay M, Shepherd J et al. Prevalence of mental health conditions and brain fog in people with long COVID: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2024.
17. Natarajan A Shetty A Delanerolle G Zeng Y Zhang Y Raymont V A systematic review and meta-analysis of long COVID symptoms Syst Rev 2023 12 1 88 10.1186/s13643-023-02250-0 37245047
Natarajan A, Shetty A, Delanerolle G, Zeng Y, Zhang Y, Raymont V, et al. A systematic review and meta-analysis of long COVID symptoms. Syst Rev. 2023;12(1):88.37245047 10.1186/s13643-023-02250-0
18. Guillen-Burgos HF Galvez-Florez JF Moreno-Lopez S Gonzalez I Guillen M Anaya J-M Factors associated with mental health outcomes after COVID-19: a 24-month follow-up longitudinal study Gen Hosp Psychiatry 2023 84 241 9 10.1016/j.genhosppsych.2023.08.009 37690207
Guillen-Burgos HF, Galvez-Florez JF, Moreno-Lopez S, Gonzalez I, Guillen M, Anaya J-M. Factors associated with mental health outcomes after COVID-19: a 24-month follow-up longitudinal study. Gen Hosp Psychiatry. 2023;84:241–9.37690207 10.1016/j.genhosppsych.2023.08.009
19. Lazarus RS, Folkman S. Stress, appraisal, and coping. Springer publishing company; 1984.
20. Wolf-Kühn N, Morfeld M, Rehabilitationspsychologie. Springer publishing company. 2016. 31–47.
21. Bisschop MI Kriegsman DMW Beekman ATF Deeg DJH Chronic diseases and depression: the modifying role of psychosocial resources Soc Sci Med 2004 59 4 721 33 10.1016/j.socscimed.2003.11.038 15177830
Bisschop MI, Kriegsman DMW, Beekman ATF, Deeg DJH. Chronic diseases and depression: the modifying role of psychosocial resources. Soc Sci Med. 2004;59(4):721–33.15177830 10.1016/j.socscimed.2003.11.038
22. Antonovsky A Unraveling the mystery of health: how people manage stress and stay well 1987 San Francisco, CA, US Jossey-Bass
Antonovsky A. Unraveling the mystery of health: how people manage stress and stay well. San Francisco, CA, US: Jossey-Bass; 1987.
23. Löwe B Toussaint A Rosmalen JG Huang W-L Burton C Weigel A Persistent physical symptoms: definition, genesis, and management Lancet 2024 403 10444 2649 62 10.1016/S0140-6736(24)00623-8 38879263
Löwe B, Toussaint A, Rosmalen JG, Huang W-L, Burton C, Weigel A, et al. Persistent physical symptoms: definition, genesis, and management. Lancet. 2024;403(10444):2649–62.38879263 10.1016/S0140-6736(24)00623-8
24. Sykes DL Holdsworth L Jawad N Gunasekera P Morice AH Crooks MG Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung 2021 199 113 9 10.1007/s00408-021-00423-z 33569660
Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung. 2021;199:113–9.33569660 10.1007/s00408-021-00423-z
25. Yelin D Wirtheim E Vetter P Kalil AC Bruchfeld J Runold M Long-term consequences of COVID-19: research needs Lancet Infect Dis 2020 20 10 1115 7 10.1016/S1473-3099(20)30701-5 32888409
Yelin D, Wirtheim E, Vetter P, Kalil AC, Bruchfeld J, Runold M, et al. Long-term consequences of COVID-19: research needs. Lancet Infect Dis. 2020;20(10):1115–7.32888409 10.1016/S1473-3099(20)30701-5
26. Pignon B Matta J Wiernik E Toussaint A Loewe B Robineau O Psychological burden associated with incident persistent symptoms and their evolution during the COVID-19 pandemic: a prospective population-based study BMJ Ment Health 2024 27 1 e300907 10.1136/bmjment-2023-300907 38490690
Pignon B, Matta J, Wiernik E, Toussaint A, Loewe B, Robineau O, et al. Psychological burden associated with incident persistent symptoms and their evolution during the COVID-19 pandemic: a prospective population-based study. BMJ Ment Health. 2024;27(1):e300907.38490690 10.1136/bmjment-2023-300907
27. Kuut TA Muller F Csorba I Braamse A Aldenkamp A Appelman B Efficacy of cognitive-behavioral therapy targeting severe fatigue following Coronavirus Disease 2019: results of a Randomized Controlled Trial Clin Infect Dis 2023 77 5 687 95 10.1093/cid/ciad257 37155736
Kuut TA, Muller F, Csorba I, Braamse A, Aldenkamp A, Appelman B, et al. Efficacy of cognitive-behavioral therapy targeting severe fatigue following Coronavirus Disease 2019: results of a randomized controlled trial. Clin Infect Dis. 2023;77(5):687–95.37155736 10.1093/cid/ciad257
28. Huth D Brascher AK Tholl S Fiess J Birke G Herrmann C Cognitive-behavioral therapy for patients with post-COVID-19 condition (CBT-PCC): a feasibility trial Psychol Med 2024 54 6 1122 32 10.1017/S0033291723002921 37842765
Huth D, Brascher AK, Tholl S, Fiess J, Birke G, Herrmann C, et al. Cognitive-behavioral therapy for patients with post-COVID-19 condition (CBT-PCC): a feasibility trial. Psychol Med. 2024;54(6):1122–32.37842765 10.1017/S0033291723002921
29. Kupferschmitt A Langheim E Tuter H Etzrodt F Loew TH Kollner V First results from post-COVID inpatient rehabilitation Front Rehabil Sci 2022 3 1093871 10.3389/fresc.2022.1093871 36756465
Kupferschmitt A, Langheim E, Tuter H, Etzrodt F, Loew TH, Köllner V. First results from post-COVID inpatient rehabilitation. Front Rehabil Sci. 2022;3:1093871.36756465 10.3389/fresc.2022.1093871
30. Madl M Lieb M Schieber K Hepp T Erim Y A taxonomy for psycho-oncological intervention techniques in an Acute Care Hospital in Germany Oncol Res Treat 2021 44 7–8 382 9 10.1159/000517532 34237721
Madl M, Lieb M, Schieber K, Hepp T, Erim Y. A taxonomy for psycho-oncological intervention techniques in an acute care hospital in Germany. Oncol Res Treat. 2021;44(7–8):382–9.34237721 10.1159/000517532
31. Ma R-C Yin Y-Y Wang Y-Q Liu X Xie J Effectiveness of cognitive behavioural therapy for chronic obstructive pulmonary disease patients: a systematic review and meta-analysis Complement Ther Clin Pract 2020 38 101071 10.1016/j.ctcp.2019.101071 31743870
Ma R-C, Yin Y-Y, Wang Y-Q, Liu X, Xie J. Effectiveness of cognitive behavioural therapy for chronic obstructive pulmonary disease patients: a systematic review and meta-analysis. Complement Ther Clin Pract. 2020;38:101071.31743870 10.1016/j.ctcp.2019.101071
32. Sommaruga M, Pierobon A. Psychotherapy and psychological support for severe heart conditions. Brain and Heart Dynamics. 2020:411 – 25.
33. Neill J Belan I Ried K Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review J Adv Nurs 2006 56 6 617 35 10.1111/j.1365-2648.2006.04054.x 17118041
Neill J, Belan I, Ried K. Effectiveness of non-pharmacological interventions for fatigue in adults with multiple sclerosis, rheumatoid arthritis, or systemic lupus erythematosus: a systematic review. J Adv Nurs. 2006;56(6):617–35.17118041 10.1111/j.1365-2648.2006.04054.x
34. Dettmers C Sulzmann M Ruchay-Plössl A Gütler R Vieten M Endurance exercise improves walking distance in MS patients with fatigue Acta Neurol Scand 2009 120 4 251 7 10.1111/j.1600-0404.2008.01152.x 19178385
Dettmers C, Sulzmann M, Ruchay-Plössl A, Gütler R, Vieten M. Endurance exercise improves walking distance in MS patients with fatigue. Acta Neurol Scand. 2009;120(4):251–7.19178385 10.1111/j.1600-0404.2008.01152.x
35. Hermann M Pekacka-Egli A-M Witassek F Baumgaertner R Schoendorf S Spielmanns M Feasibility and efficacy of cardiopulmonary rehabilitation after COVID-19 Am J Phys Med Rehabil 2020 99 10 865 9 10.1097/PHM.0000000000001549 32732746
Hermann M, Pekacka-Egli A-M, Witassek F, Baumgaertner R, Schoendorf S, Spielmanns M. Feasibility and efficacy of cardiopulmonary rehabilitation after COVID-19. Am J Phys Med Rehabil. 2020;99(10):865–9.32732746 10.1097/PHM.0000000000001549
36. Daynes E Gerlis C Chaplin E Gardiner N Singh SJ Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition–A cohort study Chron Respir Dis 2021 18 14799731211015691 10.1177/14799731211015691 33957805
Daynes E, Gerlis C, Chaplin E, Gardiner N, Singh SJ. Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition–A cohort study. Chron Respir Dis. 2021;18:14799731211015691.33957805 10.1177/14799731211015691
37. Ahmadi Hekmatikar AH Ferreira Junior JB Shahrbanian S Suzuki K Functional and psychological changes after exercise training in post-COVID-19 patients discharged from the hospital: a PRISMA-compliant systematic review Int J Environ Health Res Pub Health 2022 19 4 2290 10.3390/ijerph19042290
Ahmadi Hekmatikar AH, Ferreira Junior JB, Shahrbanian S, Suzuki K. Functional and psychological changes after exercise training in post-COVID-19 patients discharged from the hospital: a PRISMA-compliant systematic review. Int J Environ Health Res Pub Health. 2022;19(4):2290.10.3390/ijerph19042290
38. Stussman B Williams A Snow J Gavin A Scott R Nath A Characterization of post–exertional malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome Front Neurol 2020 11 1025 10.3389/fneur.2020.01025 33071931
Stussman B, Williams A, Snow J, Gavin A, Scott R, Nath A, et al. Characterization of post–exertional malaise in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Front Neurol. 2020;11:1025.33071931 10.3389/fneur.2020.01025
39. Abonie US Sandercock GRH Heesterbeek M Hettinga FJ Effects of activity pacing in patients with chronic conditions associated with fatigue complaints: a meta-analysis Disabil Rehabil 2020 42 5 613 22 10.1080/09638288.2018.1504994 30449204
Abonie US, Sandercock GRH, Heesterbeek M, Hettinga FJ. Effects of activity pacing in patients with chronic conditions associated with fatigue complaints: a meta-analysis. Disabil Rehabil. 2020;42(5):613–22.30449204 10.1080/09638288.2018.1504994
40. Getu MA Wang P Addissie A Seife E Chen C Kantelhardt EJ The effect of cognitive behavioural therapy integrated with activity pacing on cancer-related fatigue, depression and quality of life among patients with breast cancer undergoing chemotherapy in Ethiopia: a randomised clinical trial Int J Cancer 2023 152 12 2541 53 10.1002/ijc.34452 36744446
Getu MA, Wang P, Addissie A, Seife E, Chen C, Kantelhardt EJ. The effect of cognitive behavioural therapy integrated with activity pacing on cancer-related fatigue, depression and quality of life among patients with breast cancer undergoing chemotherapy in Ethiopia: a randomised clinical trial. Int J Cancer. 2023;152(12):2541–53.36744446 10.1002/ijc.34452
41. Casson S Jones MD Cassar J Kwai N Lloyd AR Barry BK The effectiveness of activity pacing interventions for people with chronic fatigue syndrome: a systematic review and meta-analysis Disabil Rehabil 2023 45 23 3788 802 10.1080/09638288.2022.2135776 36345726
Casson S, Jones MD, Cassar J, Kwai N, Lloyd AR, Barry BK, et al. The effectiveness of activity pacing interventions for people with chronic fatigue syndrome: a systematic review and meta-analysis. Disabil Rehabil. 2023;45(23):3788–802.36345726 10.1080/09638288.2022.2135776
42. Duñabeitia JA Mera F Baro Ó Jadad-Garcia T Jadad AR Personalized computerized training for cognitive dysfunction after COVID-19: a before-and-after feasibility pilot study Int J Environ Health Res Pub Health 2023 20 4 3100 10.3390/ijerph20043100
Duñabeitia JA, Mera F, Baro Ó, Jadad-Garcia T, Jadad AR. Personalized computerized training for cognitive dysfunction after COVID-19: a before-and-after feasibility pilot study. Int J Environ Health Res Pub Health. 2023;20(4):3100.10.3390/ijerph20043100
43. Chan AW Tetzlaff JM Altman DG Laupacis A Gotzsche PC Krleza-Jeric K SPIRIT 2013 statement: defining standard protocol items for clinical trials Ann Intern Med 2013 158 3 200 7 10.7326/0003-4819-158-3-201302050-00583 23295957
Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–7.23295957 10.7326/0003-4819-158-3-201302050-00583
44. Kupferschmitt A Etzrodt F Kleinschmidt J Köllner V Nicht Nur multimodal, sondern auch interdisziplinär: Ein Konzept für fächerübergreifende Zusammenarbeit in Der Rehabilitation Des Post-COVID-Syndroms. PPmP-Psychotherapie· Psychosomatik· Medizinische Psychologie 2023 73 01 34 41
Kupferschmitt A, Etzrodt F, Kleinschmidt J, Köllner V. Nicht nur multimodal, sondern auch interdisziplinär: Ein Konzept für fächerübergreifende Zusammenarbeit in der Rehabilitation des Post-COVID-Syndroms. PPmP-Psychotherapie· Psychosomatik·. Medizinische Psychologie. 2023;73(01):34–41.
45. NeuroNation MED. https://neuronation-med.de/ Accessed 25 July 2024.
46. Laquai S Genesen heißt nicht gesund–chronisches fatigue-syndrom nach Covid-19-Erkrankung Physiopraxis 2021 19 06 30 3 10.1055/a-1492-5147
Laquai S. Genesen heißt nicht gesund–chronisches Fatigue-Syndrom nach Covid-19-Erkrankung. Physiopraxis. 2021;19(06):30–3.10.1055/a-1492-5147
47. Zamunér AR Moreno MA Camargo TM Graetz JP Rebelo AC Tamburús NY Assessment of subjective perceived exertion at the anaerobic threshold with the Borg CR-10 scale J Sports Sci Med 2011 10 1 130 24149305
Zamunér AR, Moreno MA, Camargo TM, Graetz JP, Rebelo AC, Tamburús NY, et al. Assessment of subjective perceived exertion at the anaerobic threshold with the Borg CR-10 scale. J Sports Sci Med. 2011;10(1):130.24149305
48. Bahmer T, Borzikowsky C, Lieb W, Horn A, Krist L, Fricke J et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study. EClinicalMedicine. 2022;51.
49. Kroenke K Spitzer RL Williams JB The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms Psychosom Med 2002 64 2 258 66 10.1097/00006842-200203000-00008 11914441
Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64(2):258–66.11914441 10.1097/00006842-200203000-00008
50. Kroenke K Spitzer RL Williams JB The PHQ-9: validity of a brief depression severity measure J Gen Intern Med 2001 16 9 606 13 10.1046/j.1525-1497.2001.016009606.x 11556941
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.11556941 10.1046/j.1525-1497.2001.016009606.x
51. Spitzer RL Kroenke K Williams JB Lowe B A brief measure for assessing generalized anxiety disorder: the GAD-7 Arch Intern Med 2006 166 10 1092 7 10.1001/archinte.166.10.1092 16717171
Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.16717171 10.1001/archinte.166.10.1092
52. Krupp LB LaRocca NG Muir-Nash J Steinberg AD The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus Arch Neurol 1989 46 10 1121 3 10.1001/archneur.1989.00520460115022 2803071
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.2803071 10.1001/archneur.1989.00520460115022
53. Cotler J, Holtzman C, Dudun C, Jason LA. A brief questionnaire to assess post-exertional malaise. Diagnostics (Basel). 2018;8(3).
54. Behrends U. Screening auf Post-exertionelle-malaise (PEM): Klinikum rechts Der Isar Technische Universitäts München; 2021 https://cfc.charite.de/fileadmin/user_upload/microsites/kompetenzzentren/cfc/ZZ_alte_Dateien/Landing_Page/DSQ-PEM_TUM.pdf#:~:text=Screening%20auf. Accessed 11 July 2024.
55. Morin CM Belleville G Bélanger L Ivers H The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response Sleep 2011 34 5 601 8 10.1093/sleep/34.5.601 21532953
Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601–8.21532953 10.1093/sleep/34.5.601
56. Gerber M Lang C Lemola S Colledge F Kalak N Holsboer-Trachsler E Validation of the German version of the insomnia severity index in adolescents, young adults and adult workers: results from three cross-sectional studies BMC Psych 2016 16 1 174 10.1186/s12888-016-0876-8
Gerber M, Lang C, Lemola S, Colledge F, Kalak N, Holsboer-Trachsler E, et al. Validation of the German version of the insomnia severity index in adolescents, young adults and adult workers: results from three cross-sectional studies. BMC Psych. 2016;16(1):174.10.1186/s12888-016-0876-8
57. Cordes A Herrmann-Lingen C Büchner B Hessel A Repräsentative Normierung Des ENRICHD-Social-Support-Instrument (ESSI)-Deutsche Version Klinische Diagnostik und Evaluation 2009 2 1 16 32
Cordes A, Herrmann-Lingen C, Büchner B, Hessel A. Repräsentative normierung des ENRICHD-social-support-instrument (ESSI)-deutsche version. Klinische Diagnostik und Evaluation. 2009;2(1):16–32.
58. Schmalbach B Tibubos AN Zenger M Hinz A Brähler E Psychometrische evaluation und normwerte einer Ultrakurzform Der sense of coherence scale SOC-3. [Psychometric evaluation and norm values of an ultra-short version of the sense of coherence scale SOC-3] Psychother Psychosom Med Psychol 2020 70 2 86 93 10.1055/a-0901-7054 31315141
Schmalbach B, Tibubos AN, Zenger M, Hinz A, Brähler E. Psychometrische evaluation und normwerte einer ultrakurzform der sense of coherence scale SOC-3. [Psychometric evaluation and norm values of an ultra-short version of the sense of coherence scale SOC-3]. Psychother Psychosom Med Psychol. 2020;70(2):86–93.31315141 10.1055/a-0901-7054
59. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav. 1983:385–96.
60. Toussaint A Murray AM Voigt K Herzog A Gierk B Kroenke K Development and validation of the somatic Symptom Disorder–B criteria scale (SSD-12) Psychosom Med 2016 78 1 5 12 10.1097/PSY.0000000000000240 26461855
Toussaint A, Murray AM, Voigt K, Herzog A, Gierk B, Kroenke K, et al. Development and validation of the somatic Symptom Disorder–B criteria scale (SSD-12). Psychosom Med. 2016;78(1):5–12.26461855 10.1097/PSY.0000000000000240
61. Aderhold C Morawa E Paslakis G Erim Y Entwicklung Und Validierung eines Fragebogens Zur Patientenkompetenz Im Umgang Mit Einer Krebserkrankung (PUK) Z Psychosom Med Psychother 2019 65 3 239 56 31476991
Aderhold C, Morawa E, Paslakis G, Erim Y. Entwicklung und validierung eines fragebogens zur patientenkompetenz im umgang mit einer krebserkrankung (PUK). Z Psychosom Med Psychother. 2019;65(3):239–56.31476991
62. Morfeld M, Kirchberger I, Bullinger M. SF-36 Fragebogen zum gesundheitszustand: deutsche version des short Form-36 health survey. Hogrefe. 2011.
63. Helmstaedter C Verbaler Lern-Und Merk-fahigkeitstest. Ein praktikables und differenziertes Instrumentarium Zur Prufung Der Verbalen Gedachtnisleistungen Schweiz Arch Neurol Psychiatr 1990 141 21 30 1690447
Helmstaedter C. Verbaler Lern- und Merk-Fähigkeitstest. Ein praktikables und differenziertes Instrumentarium zur Prüfung der verbalen Gedächtnisleistungen. Schweiz Arch Neurol Psychiatr. 1990;141:21–30.1690447
64. Härting C Markowitsch HJ Neufeld H Calabrese P Deisinger K Kessler J Wechsler Gedächtnis Test-Revidierte Fassung (WMS-R) 2000 Bern Huber
Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. Wechsler Gedächtnistest-revidierte Fassung (WMS-R). Bern: Huber. 2000.
65. Reitan RM. Trail making test: Manual for administration and scoring. Reitan Neuropsychology Laboratory; 1986.
66. Brickenkamp R, Schmidt-Atzert L, Liepmann D. Test d2-revision: aufmerksamkeits- und konzentrationstest. Hogrefe Göttingen. 2010.
67. Aschenbrenner S, Tucha O, Lange KW. Regensburger wortflüssigkeitstest: RWT. Hogrefe, Verlag für Psychologie. 2000.
68. Heartbeat Medical [https://heartbeat-med.com/de/ Accessed 24 July 2024.
69. Harris PA Taylor R Thielke R Payne J Gonzalez N Conde JG Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support J Biomed Inf 2009 42 2 377 81 10.1016/j.jbi.2008.08.010
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.10.1016/j.jbi.2008.08.010
70. Harris PA Taylor R Minor BL Elliott V Fernandez M O’Neal L The REDCap consortium: building an international community of software platform partners J Biomed Inf 2019 95 103208 10.1016/j.jbi.2019.103208
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inf. 2019;95:103208.10.1016/j.jbi.2019.103208
71. Faul F Erdfelder E Lang A-G Buchner A G* power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences Behav Res Methods 2007 39 2 175 91 10.3758/BF03193146 17695343
Faul F, Erdfelder E, Lang A-G, Buchner A. G* power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.17695343 10.3758/BF03193146
72. Faul F Erdfelder E Buchner A Lang A-G Statistical power analyses using G* power 3.1: tests for correlation and regression analyses Behav Res Methods 2009 41 4 1149 60 10.3758/BRM.41.4.1149 19897823
Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G* power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149–60.19897823 10.3758/BRM.41.4.1149
73. Abeling B Müller A Stephan M Pollmann I de Zwaan M Negative Effekte Von Psychotherapie: Häufigkeit Und Korrelate in Einer Klinischen Stichprobe Psychother Psychosom Med Psychol 2018 68 09/10 428 36 10.1055/s-0043-117604 28895614
Abeling B, Müller A, Stephan M, Pollmann I, de Zwaan M. Negative effekte von psychotherapie: häufigkeit und korrelate in einer klinischen stichprobe. Psychother Psychosom Med Psychol. 2018;68(09/10):428–36.28895614 10.1055/s-0043-117604
74. Berk M Parker G The Elephant on the couch: side-effects of Psychotherapy Aust N Z J Psychiatry 2009 43 9 787 94 10.1080/00048670903107559 19670051
Berk M, Parker G. The elephant on the couch: side-effects of psychotherapy. Aust N Z J Psychiatry. 2009;43(9):787–94.19670051 10.1080/00048670903107559
75. Linden M How to define, find and classify side effects in psychotherapy: from unwanted events to adverse treatment reactions Clin Psychol Psychothe 2013 20 4 286 96 10.1002/cpp.1765
Linden M. How to define, find and classify side effects in psychotherapy: from unwanted events to adverse treatment reactions. Clin Psychol Psychothe. 2013;20(4):286–96.10.1002/cpp.1765
76. Swainston K Thursby S Bell B Poulter H Dismore L Copping L What psychological interventions are effective for the management of persistent physical symptoms (PPS)? A systematic review and meta-analysis Br J Health Psychol 2023 28 1 80 97 10.1111/bjhp.12613 35837827
Swainston K, Thursby S, Bell B, Poulter H, Dismore L, Copping L. What psychological interventions are effective for the management of persistent physical symptoms (PPS)? A systematic review and meta-analysis. Br J Health Psychol. 2023;28(1):80–97.35837827 10.1111/bjhp.12613
77. Chalder T Patel M Hotopf M Moss-Morris R Ashworth M Watts K Efficacy of therapist-delivered transdiagnostic CBT for patients with persistent physical symptoms in secondary care: a randomised controlled trial Psychol Med 2023 53 2 486 96
Chalder T, Patel M, Hotopf M, Moss-Morris R, Ashworth M, Watts K, et al. Efficacy of therapist-delivered transdiagnostic CBT for patients with persistent physical symptoms in secondary care: a randomised controlled trial. Psychol Med. 2023;53(2):486–96.
78. Gay MC Cassedanne F Barbot F Vaugier I Thomas S Manchon E Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care J Neurol Neurosurg Psychiatry 2024 95 2 158 66 10.1136/jnnp-2023-331537 37648439
Gay MC, Cassedanne F, Barbot F, Vaugier I, Thomas S, Manchon E, et al. Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): a multicentre, randomised, open-label, controlled trial versus standard care. J Neurol Neurosurg Psychiatry. 2024;95(2):158–66.37648439 10.1136/jnnp-2023-331537
79. Yang X, Li Z, Sun J. Effects of cognitive behavioral therapy–based intervention on improving glycaemic, psychological, and physiological outcomes in adult patients with diabetes Mellitus: a meta-analysis of Randomized controlled trials. Front Psychiatry. 2020;11.
80. Li YN Buys N Ferguson S Li ZJ Sun J Effectiveness of cognitive behavioral therapy-based interventions on health outcomes in patients with coronary heart disease: a meta-analysis World J Psychiatry 2021 11 11 1147 66 10.5498/wjp.v11.i11.1147 34888180
Li YN, Buys N, Ferguson S, Li ZJ, Sun J. Effectiveness of cognitive behavioral therapy-based interventions on health outcomes in patients with coronary heart disease: a meta-analysis. World J Psychiatry. 2021;11(11):1147–66.34888180 10.5498/wjp.v11.i11.1147
81. Liu J Gill NS Teodorczuk A Li Z-j Sun J The efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: a meta-analysis of randomized controlled trials J Affect Disord 2019 245 98 112 10.1016/j.jad.2018.10.114 30368076
Liu J, Gill NS, Teodorczuk A, Li Z-j, Sun J. The efficacy of cognitive behavioural therapy in somatoform disorders and medically unexplained physical symptoms: a meta-analysis of randomized controlled trials. J Affect Disord. 2019;245:98–112.30368076 10.1016/j.jad.2018.10.114
82. Abbass A Lumley MA Town J Holmes H Luyten P Cooper A Short-term psychodynamic psychotherapy for functional somatic disorders: a systematic review and meta-analysis of within-treatment effects J Psychosom Res 2021 145 110473 10.1016/j.jpsychores.2021.110473 33814192
Abbass A, Lumley MA, Town J, Holmes H, Luyten P, Cooper A, et al. Short-term psychodynamic psychotherapy for functional somatic disorders: a systematic review and meta-analysis of within-treatment effects. J Psychosom Res. 2021;145:110473.33814192 10.1016/j.jpsychores.2021.110473
83. Sattel H Lahmann C Gündel H Guthrie E Kruse J Noll-Hussong M Brief psychodynamic interpersonal psychotherapy for patients with multisomatoform disorder: randomised controlled trial Br J Psychiatry 2012 200 1 60 7 10.1192/bjp.bp.111.093526 22075651
Sattel H, Lahmann C, Gündel H, Guthrie E, Kruse J, Noll-Hussong M, et al. Brief psychodynamic interpersonal psychotherapy for patients with multisomatoform disorder: randomised controlled trial. Br J Psychiatry. 2012;200(1):60–7.22075651 10.1192/bjp.bp.111.093526
84. König H König HH Konnopka A The excess costs of depression: a systematic review and meta-analysis Epidemiol Psychiatr Sci 2020 29 e30 10.1017/S2045796019000180
König H, König HH, Konnopka A. The excess costs of depression: a systematic review and meta-analysis. Epidemiol Psychiatr Sci. 2020;29:e30.10.1017/S2045796019000180
85. Hacker KA Briss PA Richardson L Wright J Petersen R COVID-19 and chronic disease: the Impact now and in the future Prev Chronic Dis 2021 18 E62 10.5888/pcd18.210086 34138696
Hacker KA, Briss PA, Richardson L, Wright J, Petersen R. COVID-19 and chronic disease: the impact now and in the future. Prev Chronic Dis. 2021;18:E62.34138696 10.5888/pcd18.210086
